Results 101 to 110 of about 5,288 (183)

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

Journal of Experimental & Clinical Cancer Research, 2017
Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is a novel anticancer drug used for treating several types of cancers.
Jin Wang, Xiaoyang Liu, Yongzhi Hong, Songtao Wang, Pin Chen, Aihua Gu, Xiaoyuan Guo, Peng Zhao   +7 more
doaj   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Conformational snapshots of Tec kinases during signaling [PDF]

, 2009
The control of cellular signaling cascades is of utmost importance in regulating the immune response. Exquisitely precise protein-protein interactions and chemical modification of substrates by enzymatic catalysis are the fundamental components of the ...
Afar, Andreotti, Andreotti, August, Baraldi, Berg, Berg, Bogin, Bose, Bradshaw, Brazin, Brazin, Breheny, Brown, Brown, Bubeck Wardenburg, Bunnell, Bunnell, Chan, Ching, Christoph Grathwohl, Colgan, Cory, Cowan-Jacob, Cozier, Deindl, DeLano, Engen, Felices, Feng, Ferguson, Filippakopoulos, Fukuda, Garcon, Goldsmith, Gomez-Rodriguez, Gothel, Haire, Hansson, Hansson, Hao, Hashimoto, Hawkins, Heyeck, Heyeck, Huang, Huang, Hubbard, Hubbard, Huse, Hyvonen, Johnson, Joseph, Joseph, Joseph, Kaneko, Kashiwakura, Kato, Kojima, Kurosaki, Laederach, Laederach, Lamers, Latour, Lee, Lee, Lemmon, Lemmon, Lemmon, Levinson, Li, Li, Li, Lin, Lin, Liu, Mallis, Manning, Mano, Mao, Marengere, Marquez, Matsushita, Mihara, Mikkola, Mohamed, Morrogh, Murayama, Nagar, Nore, Ogawa, Park, Parsons, Pawson, Perez-Villar, Pletneva, Prade, Pursglove, Qi, Rawlings, Remenyi, Salim, Scharenberg, Schlessinger, Schmidt, Schwartzberg, Severin, Shan, Shoelson, Sicheri, Siliciano, Smith, Sondhi, Su, Sun, Takata, Tamagnone, Thomas, Tomlinson, Tzeng, Ubersax, Varnai, Veillette, Vetrie, Vihinen, Wang, Wilcox, Williams, Wong, Yamadori, Yamaguchi, Yang, Yang, Yu   +133 more
core   +3 more sources

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Secreted IgM deficiency leads to increased BCR signaling that results in abnormal splenic B cell development

Scientific Reports, 2017
Mice lacking secreted IgM (sIgM −/−) antibodies display abnormal splenic B cell development, which results in increased marginal zone and decreased follicular B cell numbers. However, the mechanism by which sIgM exhibit this effect is unknown.
Dimitrios Tsiantoulas, Mate Kiss, Barbara Bartolini-Gritti, Andreas Bergthaler, Ziad Mallat, Hassan Jumaa, Christoph J. Binder   +6 more
doaj   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib

PLoS ONE, 2023
Bruton’s tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y. Lin, Amy H. Andreotti
doaj  

A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma. [PDF]

MedComm (2020), 2023
Xia Y, Li X, Jiang N, Wei X.
europepmc   +1 more source

INCREASED SURVIVAL OF CLL B CELLS IN THE PRESENCE OF MARROW MESENCHYMAL STROMAL CELLS: A NOVEL MODEL TO DEFINE NEW TARGETS FOR THERAPY [PDF]

, 2016
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the Western World, accounting for about 30% of adult leukemia, and it is characterized by the clonal expansion and accumulation of mature CD19+/CD5+/CD23+ B lymphocytes in the peripheral ...
CASTELLI, MONICA
core   +1 more source